Tags

Type your tag names separated by a space and hit enter

Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
Bone Marrow Transplant. 2011 Jan; 46(1):34-43.BM

Abstract

We retrospectively compared clinical outcomes in 1593 T-replete unrelated donor (URD) marrow transplant recipients with AML, MDS and CML who received myeloablative conditioning regimens of either BU and CY (BuCy), standard-dose Cy/TBI (1000-1260 cGy) or high-dose Cy/TBI (1320-1500 cGy). Subjects were drawn from patients transplanted between 1991 and 1999 facilitated by the National Marrow Donor Program. Patients who received high-dose Cy/TBI regimens were slightly younger, more likely to receive a mismatched transplant and to have intermediate or advanced disease compared with patients in the BuCy or standard-dose TBI group. Neutrophil recovery was significantly higher in the standard-dose CY/TBI group compared with the high-dose Cy/TBI or BuCy group. Patients who received the high-dose Cy/TBI regimen had an increased risk of developing grades III-IV aGVHD when compared with the control group who received BuCy (P = 0.011). OS, disease-free survival (DFS), TRM and relapse were not significantly different between any of the regimens. We conclude that BuCy, standard-dose and high-dose Cy/TBI regimens have equivalent efficacy profiles for OS, DFS, TRM and relapse risk in patients undergoing T-replete URD marrow transplantation for AML, CML and MDS.

Authors+Show Affiliations

Wayne State University Karmanos Cancer Center, Detroit, MI, USA. ubertij@karmanos.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

20400989

Citation

Uberti, J P., et al. "Comparative Analysis of BU and CY Versus CY and TBI in Full Intensity Unrelated Marrow Donor Transplantation for AML, CML and Myelodysplasia." Bone Marrow Transplantation, vol. 46, no. 1, 2011, pp. 34-43.
Uberti JP, Agovi MA, Tarima S, et al. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant. 2011;46(1):34-43.
Uberti, J. P., Agovi, M. A., Tarima, S., Haagenson, M., Gandham, S., Anasetti, C., Baker, K. S., Bolwell, B. J., Bornhauser, M., Chan, K. W., Copelan, E., Davies, S. M., Finke, J., Hale, G. A., Kollman, C., McCarthy, P. L., Ratanatharathorn, V., Ringdén, O., Weisdorf, D. J., & Rizzo, J. D. (2011). Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplantation, 46(1), 34-43. https://doi.org/10.1038/bmt.2010.81
Uberti JP, et al. Comparative Analysis of BU and CY Versus CY and TBI in Full Intensity Unrelated Marrow Donor Transplantation for AML, CML and Myelodysplasia. Bone Marrow Transplant. 2011;46(1):34-43. PubMed PMID: 20400989.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. AU - Uberti,J P, AU - Agovi,M-A, AU - Tarima,S, AU - Haagenson,M, AU - Gandham,S, AU - Anasetti,C, AU - Baker,K S, AU - Bolwell,B J, AU - Bornhauser,M, AU - Chan,K W, AU - Copelan,E, AU - Davies,S M, AU - Finke,J, AU - Hale,G A, AU - Kollman,C, AU - McCarthy,P L, AU - Ratanatharathorn,V, AU - Ringdén,O, AU - Weisdorf,D J, AU - Rizzo,J D, Y1 - 2010/04/19/ PY - 2010/4/20/entrez PY - 2010/4/20/pubmed PY - 2011/5/6/medline SP - 34 EP - 43 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 46 IS - 1 N2 - We retrospectively compared clinical outcomes in 1593 T-replete unrelated donor (URD) marrow transplant recipients with AML, MDS and CML who received myeloablative conditioning regimens of either BU and CY (BuCy), standard-dose Cy/TBI (1000-1260 cGy) or high-dose Cy/TBI (1320-1500 cGy). Subjects were drawn from patients transplanted between 1991 and 1999 facilitated by the National Marrow Donor Program. Patients who received high-dose Cy/TBI regimens were slightly younger, more likely to receive a mismatched transplant and to have intermediate or advanced disease compared with patients in the BuCy or standard-dose TBI group. Neutrophil recovery was significantly higher in the standard-dose CY/TBI group compared with the high-dose Cy/TBI or BuCy group. Patients who received the high-dose Cy/TBI regimen had an increased risk of developing grades III-IV aGVHD when compared with the control group who received BuCy (P = 0.011). OS, disease-free survival (DFS), TRM and relapse were not significantly different between any of the regimens. We conclude that BuCy, standard-dose and high-dose Cy/TBI regimens have equivalent efficacy profiles for OS, DFS, TRM and relapse risk in patients undergoing T-replete URD marrow transplantation for AML, CML and MDS. SN - 1476-5365 UR - https://www.unboundmedicine.com/medline/citation/20400989/Comparative_analysis_of_BU_and_CY_versus_CY_and_TBI_in_full_intensity_unrelated_marrow_donor_transplantation_for_AML_CML_and_myelodysplasia_ L2 - https://doi.org/10.1038/bmt.2010.81 DB - PRIME DP - Unbound Medicine ER -